GLP-1 Weight Loss9 min read·Published May 16, 2026

Semaglutide Dose for Weight Loss: A Step-by-Step Guide

How the standard dose escalation schedule works, why doses go up slowly, and what to do if you run into side effects.

ByDr. Marcus Holloway
Clinically reviewed by Dr. Anika Rao
Semaglutide Dose for Weight Loss: A Step-by-Step Guide

Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.

See if you qualify →

If your provider has talked with you about semaglutide for weight loss, you've probably seen a list of doses that go up over several months. That step-up plan can feel confusing at first. This guide walks through how semaglutide dosing works for weight loss, why it starts low and rises slowly, and what to do if you hit a bump along the way.

What is semaglutide and how does it support weight loss?

Semaglutide is a GLP-1 receptor agonist. That means it mimics a natural gut hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite. [1][3] When you inject semaglutide under the skin once a week, it acts on the brain's appetite centers and slows how quickly the stomach empties. Most people feel fuller sooner, stay full longer, and think about food less often.

In a large clinical trial of adults with overweight or obesity, semaglutide 2.4 mg once weekly, combined with lifestyle changes, led to an average weight loss of about 14.9% of body weight over 68 weeks, compared with 2.4% for placebo. [2] Want a deeper overview? See our primer on <a href="/learn/what-is-semaglutide">what semaglutide is</a>.

FDA-approved semaglutide doses for weight loss

Two brand-name semaglutide products come up in weight-loss conversations: Wegovy and Ozempic. Both contain the same active ingredient, but only one is FDA-approved specifically for weight management.

Wegovy dosing overview

Wegovy is FDA-approved for chronic weight management in adults and adolescents (12+) with obesity, or in adults with overweight who also have a weight-related condition like high blood pressure, type 2 diabetes, or high cholesterol. [1] It is dosed once weekly as a subcutaneous injection, with five step-up doses leading to a 2.4 mg maintenance dose.

Ozempic dosing (off-label for weight loss)

Ozempic is FDA-approved for type 2 diabetes, not weight loss. [3] Some providers prescribe it off-label for weight management. Its maintenance dose tops out at 2 mg per week, slightly lower than Wegovy's 2.4 mg. [3] For a side-by-side breakdown, see <a href="/learn/wegovy-vs-ozempic">Wegovy vs Ozempic</a>.

FeatureWegovyOzempic
Active ingredientSemaglutideSemaglutide
FDA-approved useChronic weight managementType 2 diabetes
Use for weight lossOn-labelOff-label
Maintenance dose2.4 mg weeklyUp to 2 mg weekly
RouteSubcutaneous injectionSubcutaneous injection
FrequencyOnce weeklyOnce weekly

The standard semaglutide dose escalation schedule

For Wegovy, the FDA-approved escalation moves through five doses, roughly one every four weeks, before reaching the maintenance dose. [1] Here is the standard schedule:

WeeksWeekly dosePurpose
1–40.25 mgStarting dose — body adjusts to GLP-1
5–80.5 mgFirst step up
9–121 mgSecond step up
13–161.7 mgThird step up
17+2.4 mgMaintenance dose

Week 1–4: 0.25 mg

The 0.25 mg dose is not meant to drive weight loss on its own. It's an introductory dose that helps your body get used to GLP-1 signaling. [1]

Week 5–8: 0.5 mg

Many people start noticing reduced appetite at this step. Mild nausea is common in the first days after each increase. [1]

Week 9–12: 1 mg

Appetite suppression typically becomes more consistent. Some people see steady weight loss by this point. [2]

Week 13–16: 1.7 mg

This is the last step before maintenance. If side effects are tolerable, most patients move forward as scheduled. [1]

Week 17+: 2.4 mg maintenance

The 2.4 mg dose is the target maintenance dose studied in the STEP trials and approved by the FDA for chronic weight management. [1][2]

Why doses are increased gradually

GLP-1 medications can cause gastrointestinal side effects, especially when they're new to your body or when the dose changes. The most common are nausea, vomiting, diarrhea, constipation, and reflux. [1][2] Slow escalation gives your gut time to adapt and reduces the chance that side effects become severe enough to stop treatment. [1]

For more on what to expect, see our guide to <a href="/learn/glp-1-side-effects">GLP-1 side effects</a> and our deeper dive on <a href="/learn/semaglutide-side-effects">semaglutide side effects</a>.

What to do if you miss a dose

Setting a weekly reminder on the same day each week can help. If you're new to injections, our <a href="/learn/how-to-inject-semaglutide">injection guide</a> walks through technique.

Adjusting the dose for side effects

Not everyone tolerates each step on schedule, and that's okay. Per the Wegovy label, if a patient does not tolerate a dose, the escalation can be delayed by 4 weeks. [1] If side effects remain hard to manage at the 2.4 mg maintenance dose, the label allows temporarily lowering to 1.7 mg, then re-escalating after 4 weeks. [1]

  • Eat smaller, lower-fat meals on the day of and day after your injection.
  • Sip water steadily; dehydration worsens nausea.
  • Track symptoms and share them with your provider before each titration step.
  • Tell your provider about any severe abdominal pain, persistent vomiting, or signs of dehydration — these can signal complications. [1]

How long to stay on the maintenance dose

Obesity is considered a chronic condition by the American Medical Association and major obesity societies, which means treatment is typically long-term. [5] In a clinical extension study, participants who stopped semaglutide regained about two-thirds of the weight they had lost within a year. [6] Your provider will weigh benefits, side effects, and goals to decide how long maintenance therapy makes sense for you.

Some people can stay on a lower dose (for example, 1.7 mg) if it controls their appetite and supports their goals with fewer side effects. This is a clinical judgment, not a one-size-fits-all rule. [1]

Compounded semaglutide and dosing differences

Compounded semaglutide is made by licensed compounding pharmacies, often during periods when the FDA has identified the branded products as being in shortage. [4] These versions are not FDA-approved, and the FDA has noted concerns about variations in dose, concentration, and added ingredients. [4]

Because compounded versions can come in different concentrations (for example, mg per mL rather than fixed pens), dosing instructions may not follow the exact 0.25 → 0.5 → 1 → 1.7 → 2.4 mg schedule above. The general principle — start low, increase slowly, target a maintenance dose — usually still applies. Always follow your provider's specific instructions. Learn more in our overview of <a href="/learn/compounded-semaglutide">compounded semaglutide</a>.

3-min quiz

See if semaglutide could be a fit

Eligibility depends on your BMI, medical history, and goals. A licensed Chia provider can review whether semaglutide is appropriate for you.

When to talk to your provider about your dose

Reach out to your prescribing provider if any of the following come up:

  • Nausea, vomiting, or diarrhea that doesn't improve within a week of a step-up.
  • Signs of dehydration (dizziness, dark urine, very low intake).
  • Severe stomach pain that radiates to your back — this can be a sign of pancreatitis. [1]
  • Weight loss that is faster than expected or feels unsafe.
  • No appetite change or weight loss after several months at maintenance.
  • You missed multiple weekly doses in a row.
  • You are planning a pregnancy — semaglutide is not recommended during pregnancy. [1]

Want to know if you may qualify? Our <a href="/learn/glp-1-eligibility">GLP-1 eligibility overview</a> explains the BMI and clinical criteria providers consider.

Frequently asked questions


3-min quiz

Talk to a licensed provider

If you're considering semaglutide for weight loss, a Chia provider can review your history, explain dosing, and answer your questions.

This article was written with AI assistance and reviewed by a human clinical editor before publication.

References

  1. 1.WEGOVY (semaglutide) injection — FDA Prescribing Information. U.S. Food and Drug Administration / Novo Nordisk. 2023
  2. 2.Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).. New England Journal of Medicine. 2021
  3. 3.OZEMPIC (semaglutide) injection — FDA Prescribing Information. U.S. Food and Drug Administration / Novo Nordisk. 2022
  4. 4.FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2024
  5. 5.AMA Recognizes Obesity as a Disease. American Medical Association House of Delegates Resolution 420 (A-13). 2013
  6. 6.Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.. Diabetes, Obesity and Metabolism. 2022

About this article

Dr. Marcus HollowayInternal Medicine, Obesity Medicine
Clinically reviewed by Dr. Anika RaoEndocrinology, MD

This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.

Get a personalized plan

See if GLP-1 is right for your body.

Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.

Take the 3-min quiz

Keep reading

Back to all guides